New Treatment Options for Nontuberculous Mycobacterial Lung Disease New research presented on the American Thoracic Culture 2018 International Meeting revealed that even though the incidence of nontuberculous mycobacterial lung disease is definitely raising, and current treatment plans are limited, specific NTM patients could find a potential treatment option in video-assisted thoracoscopic surgery .The existing treatment plans for NTM depend on long-term antibiotic regimens which have limited efficacy and so are challenging to tolerate.The disorder causes fatal potentially, long-lasting, fever-related seizures that usually do not yet have a typical treatment. Zogenix stocks surged almost threefold in premarket trading before settling in $28.87. The results also knocked just as much as 14 % off shares in British drugmaker GW, which is likely to file a credit card applicatoin the following month with U.S. Regulators to advertise its Dravet treatment – Epidiolex. Treatment plans for Dravet victims are small, involving a combined mix of medicines for the seizures also to prevent emergencies. Experts said that elevated the probability of both treatments getting standard therapy. The California-based company said it likely to report data from another late-stage trial in the first half of following year and remained on the right track to submit regulatory approvals for the medication in america and European countries in the next half of 2018.